Department of Radiology, Johns Hopkins School of Medicine, the Johns Hopkins Hospital, 600 N Wolfe St, MRI 143, Baltimore, MD 21287, USA.
Radiology. 2013 Aug;268(2):431-9. doi: 10.1148/radiol.13121637. Epub 2013 Apr 24.
To assess whether volumetric functional magnetic resonance (MR) results 3-4 weeks after initial intraarterial therapy can aid accurate distinction between responders and nonresponders, to determine whether overall survival (OS) is improved, and to compare volumetric functional MR response with anatomic response criteria (Response Evaluation Criteria in Solid Tumors [RECIST], modified RECIST [mRECIST], European Association for the Study of the Liver [EASL]), as well as α1-fetoprotein [AFP] level.
In this single-institution HIPAA-compliant retrospective, institutional review board-approved study, informed consent was waived; 143 patients with hepatocellular carcinoma underwent intraarterial therapy between October 2005 and February 2011. Volumetric functional MR response (25% or more increase in apparent diffusion coefficient, 65% or more decrease in enhancement) was stratified as follows: Dual-parameter responders fulfilled both criteria, single-parameter responders fulfilled one criterion, and those with stable disease (SD) fulfilled neither. RECIST, mRECIST, EASL, and AFP response criteria were determined. Kaplan-Meier technique, log-rank tests, and the Cox proportional hazards model were used to test whether OS was different per response.
OS differed significantly between single-parameter responders and dual-parameter responders (P = .01) and between single-parameter responders and those with SD (P = .001). Dual-parameter responders' response improved OS compared with single-parameter responders; risk of death decreased (hazard ratio [HR] = 0.28, P = .01). In those with SD compared with single-parameter responders, risk of death increased (HR = 2.09, P = .001). RECIST, mRECIST, and EASL stratification was short of significant; most lesions were classified as SD. Baseline AFP level increased in 55 patients; AFP responders versus AFP nonresponders had decreased risk of death (HR = 0.36, P = .002). Agreement between anatomic response criteria and volumetric functional MR findings (κ = 0.06-0.12) and between AFP response and imaging criteria (κ = -0.04 to 0.14) was low.
Volumetric functional MR response 3-4 weeks after initial intraarterial therapy showed improved OS. Volumetric functional MR was superior to current imaging (RECIST, mRECIST, and EASL) and biochemical (AFP level) response criteria.
评估初始动脉内治疗后 3-4 周的容积功能磁共振(MR)结果是否有助于准确区分应答者和无应答者,确定总生存率(OS)是否得到改善,并比较容积功能 MR 应答与解剖应答标准(实体瘤反应评估标准[RECIST]、改良 RECIST[mRECIST]、欧洲肝脏研究协会[EASL])以及α1-胎蛋白[AFP]水平。
本研究为机构审查委员会批准的单机构 HIPAA 合规性回顾性研究,豁免了知情同意。2005 年 10 月至 2011 年 2 月,143 例肝细胞癌患者接受了动脉内治疗。容积功能 MR 应答(表观扩散系数增加 25%或以上,增强减少 65%或以上)分为以下几类:双参数应答者满足两个标准,单参数应答者满足一个标准,而疾病稳定(SD)者则不符合任何标准。确定了 RECIST、mRECIST、EASL 和 AFP 应答标准。采用 Kaplan-Meier 技术、对数秩检验和 Cox 比例风险模型来检验 OS 是否因应答而异。
单参数应答者与双参数应答者之间(P=.01)以及单参数应答者与 SD 者之间(P=.001)的 OS 差异具有统计学意义。双参数应答者的反应改善了 OS,与单参数应答者相比,死亡风险降低(风险比[HR] = 0.28,P=.01)。与单参数应答者相比,SD 者的死亡风险增加(HR = 2.09,P=.001)。RECIST、mRECIST 和 EASL 分层不显著;大多数病变被归类为 SD。55 例患者的 AFP 基线水平升高;与 AFP 无应答者相比,AFP 应答者的死亡风险降低(HR = 0.36,P=.002)。解剖应答标准与容积功能 MR 结果之间(κ=0.06-0.12)以及 AFP 应答与成像标准之间(κ=-0.04 至 0.14)的一致性较低。
初始动脉内治疗后 3-4 周的容积功能 MR 反应显示出改善的 OS。容积功能 MR 优于当前的成像(RECIST、mRECIST 和 EASL)和生化(AFP 水平)应答标准。